Cargando…
Durability of Protection Post–Primary COVID-19 Vaccination in the United States
The durability of immune responses after COVID-19 vaccination will drive long-term vaccine effectiveness across settings and may differ by vaccine type. To determine durability of protection of COVID-19 vaccines (BNT162b2, mRNA-1273, and Ad26.COV2.S) following primary vaccination in the United State...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505933/ https://www.ncbi.nlm.nih.gov/pubmed/36146536 http://dx.doi.org/10.3390/vaccines10091458 |
_version_ | 1784796596953677824 |
---|---|
author | Zheutlin, Amanda Ott, Miles Sun, Ran Zemlianskaia, Natalia Meyer, Craig S. Rubel, Meagan Hayden, Jennifer Neri, Breno Kamath, Tripthi Khan, Najat Schneeweiss, Sebastian Sarsour, Khaled |
author_facet | Zheutlin, Amanda Ott, Miles Sun, Ran Zemlianskaia, Natalia Meyer, Craig S. Rubel, Meagan Hayden, Jennifer Neri, Breno Kamath, Tripthi Khan, Najat Schneeweiss, Sebastian Sarsour, Khaled |
author_sort | Zheutlin, Amanda |
collection | PubMed |
description | The durability of immune responses after COVID-19 vaccination will drive long-term vaccine effectiveness across settings and may differ by vaccine type. To determine durability of protection of COVID-19 vaccines (BNT162b2, mRNA-1273, and Ad26.COV2.S) following primary vaccination in the United States, a matched case-control study was conducted in three cohorts between 1 January and 7 September 2021 using de-identified data from a database covering 168 million lives. Odds ratios (ORs) for developing outcomes of interest (breakthrough SARS-CoV-2 infection, hospitalization, or intensive care unit admission) were determined for each vaccine (no direct comparisons). In total, 17,017,435 individuals were identified. Relative to the baseline, stable protection was observed for Ad26.COV2.S against infections (OR [95% confidence interval (CI)], 1.31 [1.18–1.47]) and hospitalizations (OR [95% CI], 1.25 [0.86–1.80]). Relative to the baseline, protection waned over time against infections for BNT162b2 (OR [95% CI], 2.20 [2.01–2.40]) and mRNA-1273 (OR [95% CI], 2.07 [1.87–2.29]) and against hospitalizations for BNT162b2 (OR [95% CI], 2.38 [1.79–3.17]). Baseline protection remained stable for intensive care unit admissions for all three vaccines. Calculated baseline VE was consistent with published literature. This study suggests that the three vaccines in three separate populations may have different durability profiles. |
format | Online Article Text |
id | pubmed-9505933 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95059332022-09-24 Durability of Protection Post–Primary COVID-19 Vaccination in the United States Zheutlin, Amanda Ott, Miles Sun, Ran Zemlianskaia, Natalia Meyer, Craig S. Rubel, Meagan Hayden, Jennifer Neri, Breno Kamath, Tripthi Khan, Najat Schneeweiss, Sebastian Sarsour, Khaled Vaccines (Basel) Article The durability of immune responses after COVID-19 vaccination will drive long-term vaccine effectiveness across settings and may differ by vaccine type. To determine durability of protection of COVID-19 vaccines (BNT162b2, mRNA-1273, and Ad26.COV2.S) following primary vaccination in the United States, a matched case-control study was conducted in three cohorts between 1 January and 7 September 2021 using de-identified data from a database covering 168 million lives. Odds ratios (ORs) for developing outcomes of interest (breakthrough SARS-CoV-2 infection, hospitalization, or intensive care unit admission) were determined for each vaccine (no direct comparisons). In total, 17,017,435 individuals were identified. Relative to the baseline, stable protection was observed for Ad26.COV2.S against infections (OR [95% confidence interval (CI)], 1.31 [1.18–1.47]) and hospitalizations (OR [95% CI], 1.25 [0.86–1.80]). Relative to the baseline, protection waned over time against infections for BNT162b2 (OR [95% CI], 2.20 [2.01–2.40]) and mRNA-1273 (OR [95% CI], 2.07 [1.87–2.29]) and against hospitalizations for BNT162b2 (OR [95% CI], 2.38 [1.79–3.17]). Baseline protection remained stable for intensive care unit admissions for all three vaccines. Calculated baseline VE was consistent with published literature. This study suggests that the three vaccines in three separate populations may have different durability profiles. MDPI 2022-09-03 /pmc/articles/PMC9505933/ /pubmed/36146536 http://dx.doi.org/10.3390/vaccines10091458 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Zheutlin, Amanda Ott, Miles Sun, Ran Zemlianskaia, Natalia Meyer, Craig S. Rubel, Meagan Hayden, Jennifer Neri, Breno Kamath, Tripthi Khan, Najat Schneeweiss, Sebastian Sarsour, Khaled Durability of Protection Post–Primary COVID-19 Vaccination in the United States |
title | Durability of Protection Post–Primary COVID-19 Vaccination in the United States |
title_full | Durability of Protection Post–Primary COVID-19 Vaccination in the United States |
title_fullStr | Durability of Protection Post–Primary COVID-19 Vaccination in the United States |
title_full_unstemmed | Durability of Protection Post–Primary COVID-19 Vaccination in the United States |
title_short | Durability of Protection Post–Primary COVID-19 Vaccination in the United States |
title_sort | durability of protection post–primary covid-19 vaccination in the united states |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9505933/ https://www.ncbi.nlm.nih.gov/pubmed/36146536 http://dx.doi.org/10.3390/vaccines10091458 |
work_keys_str_mv | AT zheutlinamanda durabilityofprotectionpostprimarycovid19vaccinationintheunitedstates AT ottmiles durabilityofprotectionpostprimarycovid19vaccinationintheunitedstates AT sunran durabilityofprotectionpostprimarycovid19vaccinationintheunitedstates AT zemlianskaianatalia durabilityofprotectionpostprimarycovid19vaccinationintheunitedstates AT meyercraigs durabilityofprotectionpostprimarycovid19vaccinationintheunitedstates AT rubelmeagan durabilityofprotectionpostprimarycovid19vaccinationintheunitedstates AT haydenjennifer durabilityofprotectionpostprimarycovid19vaccinationintheunitedstates AT neribreno durabilityofprotectionpostprimarycovid19vaccinationintheunitedstates AT kamathtripthi durabilityofprotectionpostprimarycovid19vaccinationintheunitedstates AT khannajat durabilityofprotectionpostprimarycovid19vaccinationintheunitedstates AT schneeweisssebastian durabilityofprotectionpostprimarycovid19vaccinationintheunitedstates AT sarsourkhaled durabilityofprotectionpostprimarycovid19vaccinationintheunitedstates |